Background: In 1996, the provincial government in Ontario, Canada required pharmaceutical manufacturers seeking to list their products on the provincial formulary to provide a formal economic analysis documenting the products' cost effectiveness. The provincial formulary lists pharmaceutical products for ...
Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary. Health Policy, 91(2), 142-147.Lexchin J. Pricing of multiple dosage prescription medications: an analysis of the Ontario drug benefit formulary. Health Pol, 2009; 91: 142-7....
High resource beneficiaries of the Ontario drug benefit (ODB) formularyCamacho, XGomes, TJuurlink, DPaterson, MDhalla, IMamdani, M
CA2 THE USE OF RESEARCH ABSTRACTS IN FORMULARY DECISION MAKING BYTHE ONTARIO CANCER DRUG APPROVAL COMMITTEEdoi:10.1016/S1098-3015(10)70026-7A WeizmanC BellElsevier Inc.Value in Health
Purpose: High-strength opioid formulations were delisted (removed) from Ontario's public drug formulary in January 2017, except for palliative patients. We evaluated the impact of this policy on opioid utilization and dosing.Martins, DianaKhuu, WayneTadrous, MinaJuurlink, David N.Mamdani, Muhammad...
Impact of formulary policy on thiazolidinedione (TZD) use in the ontario drug benefit (ODB) programClinical Pharmacology & Therapeutics, the most cited journal publishing primary investigation in pharmacology and pharmacy, is the authoritative, cross-disciplinary journal in experimental and clinical ...